Skip to main content
Erschienen in: Intensive Care Medicine 11/2012

01.11.2012 | Original

Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?

verfasst von: Miet Schetz, Sophie Van Cromphaut, Jasperina Dubois, Greet Van den Berghe

Erschienen in: Intensive Care Medicine | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The need for continuous anticoagulation remains a significant drawback in continuous renal replacement therapy (CRRT), especially in patients with increased bleeding risk. Polyethyleneimine treatment of the AN69 membrane (AN69ST) reduces thrombogenicity through decreased contact activation and promotion of heparin binding. The aim of this study is to evaluate whether this membrane prolongs filter survival in CRRT without anticoagulation.

Methods

A single-center, prospective, randomized, double-blind controlled trial with cross-over design comparing filter survival with the AN69ST membrane and the original AN69 membrane in 39 patients treated with continuous venovenous hemofiltraton (CVVH) without additional heparin.

Results

Filter survival with the AN69ST membrane (n = 75) was 14.2 ± 8.2 h, which is not significantly different from the 13.3 ± 10.3 h for the original AN69 membrane (n = 76; p = 0.59). Limiting the analysis to those treatments that were interrupted for filter clotting yielded similar results: 14.4 ± 8.2 h for the AN69 ST membrane (n = 62) versus 14.1 ± 7.5 h for the original AN69 membrane (n = 56) (p = 0.93).

Conclusions

Compared with the original AN69 membrane, the surface-treated AN69ST membrane does not prolong filter survival during CVVH without systemic anticoagulation and with the CRRT settings used in this study.
Literatur
1.
Zurück zum Zitat Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR (2006) Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 32:188–202PubMedCrossRef Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR (2006) Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 32:188–202PubMedCrossRef
2.
Zurück zum Zitat Oudemans-van Straaten HM (2010) Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif 29:191–196PubMedCrossRef Oudemans-van Straaten HM (2010) Citrate anticoagulation for continuous renal replacement therapy in the critically ill. Blood Purif 29:191–196PubMedCrossRef
3.
Zurück zum Zitat Thomas M, Valette P, Mausset AL, Déjardin P (2000) High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 23:20–26PubMed Thomas M, Valette P, Mausset AL, Déjardin P (2000) High molecular weight kininogen adsorption on hemodialysis membranes: influence of pH and relationship with contact phase activation of blood plasma. influence of pre-treatment with poly(ethyleneimine). Int J Artif Organs 23:20–26PubMed
4.
Zurück zum Zitat Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M (2005) Assessment of heparin binding to the AN69 ST hemodialysis membrane: I Preclinical studies. ASAIO J 51:342–347PubMedCrossRef Chanard J, Lavaud S, Paris B, Toure F, Rieu P, Renaux JL, Thomas M (2005) Assessment of heparin binding to the AN69 ST hemodialysis membrane: I Preclinical studies. ASAIO J 51:342–347PubMedCrossRef
5.
Zurück zum Zitat Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Canard J (2005) Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 51:348–351PubMedCrossRef Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P, Canard J (2005) Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 51:348–351PubMedCrossRef
6.
Zurück zum Zitat Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y (2007) Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 49:642–649PubMedCrossRef Evenepoel P, Dejagere T, Verhamme P, Claes K, Kuypers D, Bammens B, Vanrenterghem Y (2007) Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis 49:642–649PubMedCrossRef
7.
Zurück zum Zitat Richtrova P, Rulcova K, Mares J, Reischig T (2010) Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs 35:83–88CrossRef Richtrova P, Rulcova K, Mares J, Reischig T (2010) Evaluation of three different methods to prevent dialyzer clotting without causing systemic anticoagulation effect. Artif Organs 35:83–88CrossRef
8.
Zurück zum Zitat Sagedal S, Witczak BJ, Osnes K, Hartmann A, Os I, Eikvar L, Klingenberg O, Brosstad F (2011) A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F × 8). Blood Purif 32:151–155PubMedCrossRef Sagedal S, Witczak BJ, Osnes K, Hartmann A, Os I, Eikvar L, Klingenberg O, Brosstad F (2011) A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F × 8). Blood Purif 32:151–155PubMedCrossRef
9.
Zurück zum Zitat Brunet Ph, Frances J, Vacher-Coponat H, Jaubert D, Lebrun G, Gondouin B, Duval A, Berland Y (2011) Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60). Int J Artif Organs 34:1165–1171PubMedCrossRef Brunet Ph, Frances J, Vacher-Coponat H, Jaubert D, Lebrun G, Gondouin B, Duval A, Berland Y (2011) Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60). Int J Artif Organs 34:1165–1171PubMedCrossRef
10.
Zurück zum Zitat Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE (2009) Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy. Annals Pharmacother 43:1419–1425 (abstract)CrossRef Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE (2009) Regional Citrate Anticoagulation for PrismaFlex Continuous Renal Replacement Therapy. Annals Pharmacother 43:1419–1425 (abstract)CrossRef
11.
Zurück zum Zitat Xie W, Heidenreich S, Abbas S, Mann H (2009) Alteration of membrane properties in hemofilters during continuous hemofiltration (CVVH). ASAIO J 55:178 (abstract) Xie W, Heidenreich S, Abbas S, Mann H (2009) Alteration of membrane properties in hemofilters during continuous hemofiltration (CVVH). ASAIO J 55:178 (abstract)
12.
Zurück zum Zitat Xie WH, Heidenreich S, Vienken J, Mann H (2010) Shear stress in the hollow fibers and protein permeability during continuous hemofiltration. Int J Artif Organs 33:443 (abstract) Xie WH, Heidenreich S, Vienken J, Mann H (2010) Shear stress in the hollow fibers and protein permeability during continuous hemofiltration. Int J Artif Organs 33:443 (abstract)
13.
Zurück zum Zitat Kleger GR, Fässler E (2010) Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs 33:139–146PubMed Kleger GR, Fässler E (2010) Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs 33:139–146PubMed
14.
Zurück zum Zitat Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J (2003) Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transpl 18:2097–2104CrossRef Lavaud S, Canivet E, Wuillai A, Maheut H, Randoux C, Bonnet JM, Renaux JL, Chanard J (2003) Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane. Nephrol Dial Transpl 18:2097–2104CrossRef
15.
Zurück zum Zitat Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P (2008) The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transpl 23:2003–2009CrossRef Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P (2008) The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transpl 23:2003–2009CrossRef
16.
Zurück zum Zitat Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW (1993) Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 72:1075–1081PubMedCrossRef Kappelmayer J, Bernabei A, Edmunds LH Jr, Edgington TS, Colman RW (1993) Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res 72:1075–1081PubMedCrossRef
17.
Zurück zum Zitat Tabuchi N, Shibamiya A, Koyama T, Fukuda T, Oeveren Wv W, Sunamori M (2003) Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artif Organs 27:591–594PubMedCrossRef Tabuchi N, Shibamiya A, Koyama T, Fukuda T, Oeveren Wv W, Sunamori M (2003) Activated leukocytes adsorbed on the surface of an extracorporeal circuit. Artif Organs 27:591–594PubMedCrossRef
18.
Zurück zum Zitat Keuren JF, Wielders SJ, Willems GM, Morra M, Lindhout T (2002) Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 87:742–747PubMed Keuren JF, Wielders SJ, Willems GM, Morra M, Lindhout T (2002) Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 87:742–747PubMed
19.
Zurück zum Zitat Zemanova P, Opatmy K, Vit L, Sefma F (2005) Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes. Artif Organs 29:651–657PubMedCrossRef Zemanova P, Opatmy K, Vit L, Sefma F (2005) Tissue factor, its inhibitor, and the thrombogenicity of two new synthetic membranes. Artif Organs 29:651–657PubMedCrossRef
20.
Zurück zum Zitat Barstad RM, Hamers MJ, Møller AS, Sakariassen KS (1998) Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface. Thromb Haemost 79:302–305PubMed Barstad RM, Hamers MJ, Møller AS, Sakariassen KS (1998) Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface. Thromb Haemost 79:302–305PubMed
21.
Zurück zum Zitat Semeraro F, Ammollo CT, Semeraro N, Colucci M (2009) Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94:819–826PubMedCrossRef Semeraro F, Ammollo CT, Semeraro N, Colucci M (2009) Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94:819–826PubMedCrossRef
22.
Zurück zum Zitat Levi M, van der Poll T, ten Cate H (2006) Tissue factor in infection and severe inflammation. Semin Thromb Hemost 32:33–39PubMedCrossRef Levi M, van der Poll T, ten Cate H (2006) Tissue factor in infection and severe inflammation. Semin Thromb Hemost 32:33–39PubMedCrossRef
23.
Zurück zum Zitat Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9(Suppl 1):S9–S14PubMed Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9(Suppl 1):S9–S14PubMed
24.
Zurück zum Zitat Joannidis M, Oudemans-van Straaten HM (2007) Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 11:218PubMedCrossRef Joannidis M, Oudemans-van Straaten HM (2007) Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 11:218PubMedCrossRef
25.
Zurück zum Zitat Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639–643PubMed Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639–643PubMed
26.
Zurück zum Zitat Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 17:1568–1574PubMedCrossRef Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 17:1568–1574PubMedCrossRef
Metadaten
Titel
Does the surface-treated AN69 membrane prolong filter survival in CRRT without anticoagulation?
verfasst von
Miet Schetz
Sophie Van Cromphaut
Jasperina Dubois
Greet Van den Berghe
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 11/2012
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-012-2633-x

Weitere Artikel der Ausgabe 11/2012

Intensive Care Medicine 11/2012 Zur Ausgabe

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.